BSE: 533543 | NSE: BROOKS | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Brooks Laboratories Ltd is a below average quality company.
The key valuation ratios of Brooks Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Brooks Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9.8% | 9.7% | 2.6% | -10.6% | -8.6% | -7.8% | -5.2% | 1.9% | -11.2% | 3.5% | - |
| Value Creation Index ⓘ | -0.3 | -0.3 | -0.8 | -1.8 | -1.6 | -1.6 | -1.4 | -0.9 | -1.8 | -0.8 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 85.2 | 80 | 57.5 | 55.7 | 55 | 69.7 | 77.3 | 77 | 55.5 | 79.5 | 78 |
| Sales YoY Gr. | - | -6.1% | -28.1% | -3.2% | -1.2% | 26.6% | 10.9% | -0.4% | -27.8% | 43.1% | - |
| Adj EPS ⓘ | 3.9 | 5.4 | 0.9 | -7.1 | -7.7 | -9.4 | -6.3 | 0.1 | -3.3 | 0.5 | 0.6 |
| YoY Gr. | - | 39.9% | -84.3% | -929.4% | NA | NA | NA | NA | -2435.7% | NA | - |
| BVPS (₹) ⓘ | 56.8 | 62.3 | 65.4 | 58.4 | 50.8 | 39.5 | 25.7 | 26.1 | 22.8 | 26.5 | 26.8 |
| Adj Net Profit ⓘ | 7.6 | 10.6 | 1.7 | -13.8 | -15.1 | -23.4 | -15.7 | 0.3 | -8.2 | 1.4 | 2 |
| Cash Flow from Ops. ⓘ | 2.1 | 8.1 | 9.6 | -6.2 | -5.1 | -9.4 | -0.9 | 3.1 | 0.6 | -9.7 | - |
| Debt/CF from Ops. ⓘ | 0.2 | 0.7 | 1.4 | -4.5 | -6.2 | -2.9 | -9.3 | 1.6 | 10.3 | -0.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -0.8% | 7.6% | 1% | 43.1% | ||||
| Adj EPS ⓘ | -19.6% | NA | NA | NA | ||||
| BVPSⓘ | -8.1% | -12.2% | 1% | 16.4% | ||||
| Share Price | 17.1% | 47.3% | 18.3% | 22.4% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 6.8 | 9.1 | 1.3 | -11.4 | -13.7 | -23 | -19.3 | 0.5 | -13.4 | 2.2 | 2.3 |
| Op. Profit Mgn % ⓘ | 8.1 | 13.9 | 8.8 | -16 | -15.2 | -3.7 | 1.3 | 2.4 | -10.4 | 3.9 | 4.2 |
| Net Profit Mgn % ⓘ | 8.9 | 13.2 | 2.9 | -24.8 | -27.4 | -33.6 | -20.3 | 0.4 | -14.7 | 1.8 | 2.1 |
| Debt to Equity ⓘ | 0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 184 | 216 | 227 | 208 | 234 | 206 | 168 | 159 | 226 | 144 | 80 |
| Cash Conv. Cycle ⓘ | 22 | 25 | 2 | 7 | -7 | 7 | 34 | 31 | 29 | 19 | 20 |
Return on Equity has increased versus last 3 years average to 2.30%
Sales growth is good in last 4 quarters at 30.37%
Sales growth has been subdued in last 3 years 0.95%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.6 | -7.6 |
| TTM Sales (₹ Cr.) | 78.2 | 78.2 |
| BVPS (₹.) ⓘ | 26.8 | 22.6 |
| Reserves (₹ Cr.) ⓘ | 44 | 33 |
| P/BV ⓘ | 6.18 | 7.34 |
| PE ⓘ | 267.48 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 72.51 / 185.15 |
| All Time Low / High (₹) | 10.32 / 185.15 |
| Market Cap (₹ Cr.) | 434 |
| Equity (₹ Cr.) | 26.3 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 85 | 80 | 58 | 56 | 55 | 70 | 77 | 77 | 56 | 79 |
| Operating Expenses ⓘ | 78 | 69 | 52 | 65 | 63 | 74 | 76 | 75 | 61 | 76 |
| Manufacturing Costs | 5 | 4 | 3 | 8 | 6 | 7 | 8 | 7 | 4 | 5 |
| Material Costs | 61 | 53 | 37 | 39 | 39 | 47 | 48 | 49 | 40 | 57 |
| Employee Cost | 4 | 5 | 6 | 10 | 10 | 11 | 12 | 11 | 11 | 10 |
| Other Costs ⓘ | 9 | 7 | 6 | 8 | 8 | 9 | 9 | 8 | 6 | 5 |
| Operating Profit ⓘ | 7 | 11 | 5 | -9 | -8 | -4 | 1 | 2 | -6 | 3 |
| Operating Profit Margin (%) | 7.9% | 13.9% | 8.8% | -16.0% | -15.2% | -5.6% | 1.2% | 2.4% | -10.5% | 3.8% |
| Other Income ⓘ | 2 | 2 | 0 | 0 | 3 | 0 | 1 | 1 | 0 | 1 |
| Interest ⓘ | 0 | 1 | 1 | 2 | 3 | 3 | 3 | 1 | 1 | 1 |
| Depreciation ⓘ | 1 | 1 | 2 | 6 | 6 | 7 | 7 | 1 | 2 | 2 |
| Exceptional Items ⓘ | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 10 | 11 | 2 | -18 | -15 | -14 | -8 | 1 | -8 | 2 |
| Tax ⓘ | 1 | 0 | 1 | -4 | 0 | 11 | 7 | 0 | 0 | 0 |
| Profit After Tax | 9 | 11 | 2 | -14 | -15 | -24 | -16 | 1 | -8 | 2 |
| PAT Margin (%) | 11.1% | 13.3% | 2.9% | -24.8% | -26.9% | -35.0% | -20.2% | 0.9% | -14.7% | 1.9% |
| Adjusted EPS (₹) | 4.8 | 5.4 | 0.9 | -7.1 | -7.6 | -9.8 | -6.3 | 0.3 | -3.3 | 0.6 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 111 | 122 | 128 | 114 | 100 | 98 | 64 | 65 | 57 | 70 |
| Share Capital ⓘ | 16 | 16 | 16 | 16 | 16 | 25 | 25 | 25 | 25 | 26 |
| Reserves ⓘ | 95 | 106 | 112 | 98 | 83 | 74 | 40 | 40 | 32 | 43 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 1 | 6 | 13 | 25 | 28 | 24 | 8 | 5 | 6 | 5 |
| Long Term Debt | 0 | 0 | 11 | 17 | 14 | 11 | 1 | 0 | 0 | 0 |
| Short Term Debt | 1 | 5 | 2 | 9 | 14 | 13 | 7 | 5 | 6 | 5 |
| Trade Payables | 19 | 16 | 18 | 27 | 27 | 26 | 13 | 26 | 23 | 15 |
| Others Liabilities ⓘ | 5 | 13 | -2 | -4 | 2 | 9 | 7 | 8 | 7 | 4 |
| Total Liabilities ⓘ | 136 | 156 | 158 | 162 | 157 | 158 | 93 | 103 | 92 | 94 |
Fixed Assets | ||||||||||
| Gross Block | 21 | 23 | 127 | 132 | 132 | 133 | 20 | 21 | 23 | 23 |
| Accumulated Depreciation | 6 | 7 | 2 | 8 | 15 | 19 | 5 | 6 | 8 | 10 |
| Net Fixed Assetsⓘ | 16 | 16 | 125 | 124 | 117 | 113 | 15 | 15 | 15 | 14 |
| CWIP ⓘ | 53 | 87 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 1 | 1 | 0 | 0 | 47 | 47 | 47 | 47 |
| Inventories | 8 | 7 | 8 | 11 | 10 | 14 | 12 | 17 | 11 | 10 |
| Trade Receivables | 19 | 19 | 11 | 10 | 11 | 16 | 10 | 15 | 13 | 16 |
| Cash Equivalents | 23 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 |
| Others Assetsⓘ | 17 | 25 | 12 | 13 | 14 | 14 | 8 | 8 | 5 | 7 |
| Total Assets ⓘ | 136 | 156 | 158 | 162 | 157 | 158 | 93 | 103 | 92 | 94 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 2 | 8 | 10 | -6 | -5 | -9 | -1 | 3 | 1 | -10 |
| PBT ⓘ | 8 | 11 | 2 | -18 | -15 | -14 | -8 | 1 | -8 | 2 |
| Adjustment ⓘ | -1 | 1 | 3 | 10 | 9 | 12 | 10 | 2 | 3 | 2 |
| Changes in Working Capital ⓘ | -4 | 2 | 6 | 2 | 1 | -8 | 2 | 0 | 6 | -13 |
| Tax Paid ⓘ | -2 | -5 | -2 | -1 | -1 | 0 | -4 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | -1 | -14 | -17 | -5 | 1 | -2 | -1 | 1 | 0 | 0 |
| Capex | -11 | -34 | -17 | -6 | 1 | -2 | -1 | 1 | 0 | 0 |
| Net Investments | 8 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Others ⓘ | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 0 | 4 | 7 | 12 | 6 | 10 | 1 | -4 | 0 | 10 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | -1 | -1 | -3 | -3 | -3 | -3 | -1 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 5 | 8 | 14 | 9 | 13 | 4 | -4 | 1 | -1 |
| Net Cash Flow ⓘ | 1 | -1 | 0 | 1 | 2 | -2 | 0 | 0 | 0 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 8.59 | 9.11 | 1.33 | -11.38 | -13.83 | -24.62 | -19.17 | 1.03 | -13.44 | 2.42 |
| ROCE (%) | 9.76 | 9.69 | 2.59 | -10.64 | -8.6 | -7.77 | -5.24 | 1.87 | -11.21 | 3.5 |
| Asset Turnover Ratio | 0.64 | 0.55 | 0.41 | 0.36 | 0.35 | 0.44 | 0.62 | 0.78 | 0.57 | 0.85 |
| PAT to CFO Conversion(x) | 0.22 | 0.73 | 5 | N/A | N/A | N/A | N/A | 3 | N/A | -5 | Working Capital Days |
| Receivable Days | 77 | 87 | 83 | 67 | 72 | 71 | 59 | 58 | 91 | 67 |
| Inventory Days | 29 | 32 | 40 | 61 | 71 | 62 | 62 | 69 | 92 | 48 |
| Payable Days | 106 | 120 | 170 | 209 | 249 | 207 | 151 | 145 | 222 | 125 |
The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production.
The company has set up a well equipped manufacturing unit at Baddi, Himachal Pradesh in the year 2006 and has been awarded a G.M.P Certification for following Good Manufacturing Practices under “Revised Schedule M†of Drugs & Cosmetics Rules, 1945 in respect of various categories of Tablets, Capsules, Liquid Orals, Dry Syrups, SVP (Liquid & Dry) and Ophthalmic Section by The Health & Family Welfare Department, Himachal.
Company’s manufacturing facility at Baddi is capable of manufacturing products confirming to TRS 908 of 2003 (WHO GMP) standards. Its Quality Management System at the factory at Baddi is certified as complying to ISO 9001:2008.
Product of the company
The company has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials. These products are manufactured in accordance with highest international standards in facilities as per norms of WHO-GMP & ISO 9000-2008.
Some of the product categories are:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
